Nanobiotix (NASDAQ:NBTX) Shares Gap Down - Here's What Happened

Key Points

• Nanobiotix's stock price gapped down from a previous close of $28.23 to an opening price of $26.57 on Wednesday, and last traded at $27.82 with a volume of 22,344 shares.
• Analysts have mixed ratings on Nanobiotix, with a consensus average rating of "Hold" and a target price of $11.00, while some analysts issued a "buy" and others a "sell" rating.
• The company focuses on developing biotechnology products for cancer treatment, with its lead candidate NBTXR3 aimed at treating various types of cancer.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $28.23, but opened at $26.57. Nanobiotix shares last traded at $27.82, with a volume of 22,344 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nanobiotix in a report on Wednesday, October 8th. Finally, Leerink Partners set a $14.00 price objective on Nanobiotix in a report on Thursday, September 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $11.00.

Nanobiotix Stock Performance

The firm has a 50 day moving average price of $12.99 and a 200-day moving average price of $7.36.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.